Skip to main content
SpringerLink
Log in

High-Performance Liquid Chromatographic (HPLC) Determination of Lobenzarit in Plasma and Its Application to a Bioavailability Study in Beagle Dogs

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

A method for the quantitative determination of lobenzarit (2-[(2-carboxyphenyl)amino]-4-chlorobenzoic acid) in dog plasma by high-performance liquid chromatography with UV detection (308 nm) is described. Plasma samples (200 µl) were treated with acetonitrile and centrifuged, and the clear supernatant injected onto a reversed-phase phenyl column. The method achieved a limit of quantitation of 0.5 µg/ml in plasma, and the response was linear to 100 µg/ml. Comparing a solution and a tablet formulation given to beagle dogs, the assay demonstrated that the solution formulation was slightly more bioavailable and yielded a more variable absorption rate. The elimination of lobenzarit from plasma followed a biexponential time course, with an apparent terminal disposition half-life of between 5.8 and 10.7 hr.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. K. Ohuchi, M. Watanabe, Y. Fukui, N. Hirasawa, T. Ozeki, and S. Tsurufuji. The effect of diphenylamine derivatives on arachidonic acid metabolism in rat peritoneal macrophages. Prostaglandins Leukotrines Med. 28:15–23 (1987).

    Google Scholar 

  2. T. Takeuchi, J. Koide, O. Hosono, M. Takano, and T. Abe. CCA, N-(2-carboxyphenyl)-4-chloroanthranilic acid disodium salt, a newly developed immunomodulating drug, suppresses T-cell activation by acting on macrophages. Inflammation 13:125–135 (1989).

    Google Scholar 

  3. F. Imai, T. Suzuki, T. Ishibashi, T. Katagiri, and K. Hara. Effect of lobenzarit disodium (CCA) on B cell differentiation to antibody secreting cells. Arerugi 38:36–40 (1989).

    Google Scholar 

  4. T. Komori, T. Nakano, and Y. Ohsugi. Alleviation of depressed immunity caused by restraint-stress, by the immunomodulator, lobenzarit disodium (disodium 4-chloro-2,2′-iminodibenzoate). Int. J. Immunopharmacol. 9:433–441 (1987).

    Google Scholar 

  5. M. Fujimoto, I. Sugawara, M. Kimoto, S. Ishizaka, and T. Isujii. Immunopharmacological study of CCA (Lobenzarit disodium), an anti-arthritis agent. I. Abrogation of IL-1 secretion by LPS-stimulated human monocytes and induction of gammainterferon production with CCA. Int. J. Immunopharmacol. 8:323–328 (1986).

    Google Scholar 

  6. I. Yamamoto, H. Ohmori, and M. Sasano. Effect of N-(2-carboxyphenyl)-4-chloroanthranilic acid disodium salt (CCA) on the induction of helper and suppressor T cells in vitro and in vivo. Jpn. J. Pharmacol. 33:859–866 (1983).

    Google Scholar 

  7. Y. Ohsugi, T. Nakano, and S. Hata. A novel antiarthritic agent, CCA (lobenzarit disodium), and the role of thymus-derived lymphocytes in the inhibition of rat adjuvant arthritis. Immunopharmacology 6:15–21 (1983).

    Google Scholar 

  8. Y. Shiokawa, Y. Horiuchi, Y. Mizushima, T. Kageyama, K. Shichikawa, T. Ofuji, M. Honma, H. Yoshizawa, C. Abe, and N. Ogawa. A multicenter double-blind controlled study of lobenzarit, a novel immunomodulator, in rheumatoid arthritis. J. Rheumatol. 11:615–623 (1984).

    Google Scholar 

  9. E. Abignente and P. D. Caprariis. In K. Florey (ed.), Analytical Profiles of Drug Substances, Academic Press, New York, 1982, pp. 313–346.

    Google Scholar 

  10. L. Cotellessa, R. Riva, P. Salva, F. Marcucci, and E. Mussini. Quantitative determination of flufenamic acid in rat plasma and uterus by gas chromatography. J. Chromatogr. 192:441–445 (1980).

    Google Scholar 

  11. L. J. Dusci and L. P. Hackett. Gas-liquid chromatographic determination of mefenamic acid in human serum. J. Chromatogr. 161:340–342 (1978).

    Google Scholar 

  12. H. Roseboom and A. Hulshoff. Rapid and simple clean-up and derivatization procedure for the gc determination of acidic drugs in plasma. J. Chromatogr. 173:65–74 (1979).

    Google Scholar 

  13. M. E. Sharp. A rapid screening procedure for acidic and neutral drugs in blood by high resolution gas chromatography. J. Anal. Toxicol. 11:8–11 (1987).

    Google Scholar 

  14. O. Kubo, K. Nishide, and N. Kiriyama. Quantitative determination of flufenamic acid and its major metabolites in plasma by high performance liquid chromatography. J. Chromatogr. 174:254–257 (1979).

    Google Scholar 

  15. C. K. Lin, C. S. Lee, and J. H. Perrin. Determination of two fenamates in plasma by high-performance liquid chromatography. J. Pharm. Sci. 69:95–97 (1980).

    Google Scholar 

  16. G. G. Skellern and E. G. Salole. A high speed liquid chromatographic analysis of indomethacin in plasma. J. Chromatogr. 114:483–485 (1975).

    Google Scholar 

  17. I. M. Johansson and M. L. Eklund. Liquid chromatographic determination of meclofenamic acid in equine plasma. J. Liq. Chromatogr. 7:1609–1626 (1984).

    Google Scholar 

  18. H. J. Battista, G. Wehinger, and R. Henn. Separation and identification of nonsteroidal antirheumatic drugs containing a free carboxyl function using high-performance liquid chromatography. J. Chromatogr. 345:77–89 (1985).

    Google Scholar 

  19. G. Dannhardt, S. Laufer, and M. Lehr. HPLC determination of etofenamate and flufenamic acid in biological material. Clin. Chem. 34:2580–2581 (1988).

    Google Scholar 

  20. C. I. Omile, I. R. Tebbett, and B. Danesh. Determination of ten anti-inflammatory drugs in serum by isocratic liquid chromatography. Chromatographia 22:187–188 (1986).

    Google Scholar 

  21. O. Ishidaka, T. Shinohara, T. Tanaka, and A. Momose. Determination of mefenamic acid in horse plasma by high performance liquid chromatography. Bunseki Kagaku. 35:332–334 (1986).

    Google Scholar 

  22. M. Schulz, and A. Schmoldt. Determination of nonsteroidal antiinflammatory drugs in human plasma by high performance liquid chromatography. PZ Wiss. 2:41–44 (1989).

    Google Scholar 

  23. J. Sato, E. Owada, K. Ito, Y. Niida, A. Wakamatsu, and M. Umetsu. Simple, rapid and sensitive reversed-phase high-performance liquid chromatographic method for the determination of mefenamic acid in plasma. J. Chromatogr. 493:239–243 (1989).

    Google Scholar 

  24. K. Shimada, M. Nakajima, H. Wakabayashi, and S. Yamato. Determination of mefenamic and flufenamic acids in serum by HPLC with electrochemical detection. Bunseki Kagaku 38:632–635 (1989).

    Google Scholar 

  25. K. Ikeda, K. Uekama, M. Otagiri, and M. Hatano. Circular dichroism study on inclusion complexes of b-cyclodextrin with anti-inflammatory fenamates. J. Pharm. Sci. 63:1168–1169 (1974).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Drug Metabolism Research 7256-126-2, The Upjohn Company, 301 Henrietta Street, Kalamazoo, Michigan, 49001

    Francis J. Schwende & Scott W. Turner

Authors
  1. Francis J. Schwende
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott W. Turner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schwende, F.J., Turner, S.W. High-Performance Liquid Chromatographic (HPLC) Determination of Lobenzarit in Plasma and Its Application to a Bioavailability Study in Beagle Dogs. Pharm Res 8, 523–526 (1991). https://doi.org/10.1023/A:1015867631797

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1015867631797

Search

Navigation